Biogen Idec Inc (BIIB) 332.08 $BIIB
Why Receptos Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 10, 2:49PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Receptos , a clinical-stage...
Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...
Receptos MS Drug Yields More Good Data; Stock Jumps
at Investor's Business Daily - Wed Sep 10, 10:58AM CDT
Biotech Receptos (RCPT) shot up more than 14% in morning trading on the stock market today, just shy of an all-time high, after it released more good data from a mid-stage clinical trial of its multiple-sclerosis drug. Receptos filed a late-breaking...
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 10, 10:17AM CDT
AbbVie's (ABBV) collaboration agreement with Infinity Pharmaceuticals (INFI) was one of the top stories in the biotech sector last week.
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
Business Wire - Wed Sep 10, 6:00AM CDT
--- Patients Most Uncomfortable Engaging in Candid Dialogue about More Private Symptoms -
J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig
at The Street - Mon Sep 08, 7:48AM CDT
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Why Baxter International Offers Great Reward for Minimal Risk
at The Street - Mon Sep 08, 5:00AM CDT
Wall Street is wrong to discount Baxter's value-creating potential.
Indexes Trim Losses But Remain Lower At Midday
at Investor's Business Daily - Fri Sep 05, 11:04AM CDT
The stock market came off morning lows at midday Friday, but remained lower as some notable leaders came under fire. The Nasdaq fell 0.3% while the S&P 500 and the Dow Jones industrial average were down 0.1%. Volume was running higher on the NYSE and...
Upcoming Conferences, Dividends, Regulatory Disclosures, and Acquisitions - Research Reports on Medtronic, Humana, Shire, Biogen and Covidien
PR Newswire - Fri Sep 05, 8:05AM CDT
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.70%
Comtex SmarTrend(R) - Thu Sep 04, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.78 to a high of $344.44. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $339.18 on volume of 827,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Diplomat to distribute Plegridy(TM) (peginterferon beta-1a) for treatment of multiple sclerosis
PR Newswire - Thu Sep 04, 3:42PM CDT
Diplomat, the nation's largest independent specialty pharmacy, announced that it will distribute Plegridy(TM) (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy(TM) was approved on August 15, 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be administered subcutaneously with the Plegridy Pen, a new, ready-to-use autoinjector, or a prefilled syringe.
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
Specialty Vaccine Company PaxVax Appoints Mark Meltz Executive Vice President and Chief Legal Officer
Business Wire - Wed Sep 03, 7:01AM CDT
PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice President and Chief Legal Officer. In this role, Mr. Meltz will oversee all legal, intellectual property, business development, government affairs, compliance and corporate governance matters for the company.
Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care
Business Wire - Wed Sep 03, 7:01AM CDT
--- Innovative Programs Reinforce Commitment to Improving the Lives of People Living with MS -
Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014
Business Wire - Tue Sep 02, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference 2014. The webcast will be live on Monday, September 8, 2014 at 2:00p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Watch For Today's Momo Momentum Stock: Biogen Idec (BIIB)
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple
Biogen: Moving From Collaboration To Innovation
at Investor's Business Daily - Fri Aug 29, 3:14PM CDT
In an industry as risky as biotechnology, it's easy to stick with a proven formula. But sometimes, managing for success means changing your strategic direction to avoid falling into a rut. After two decades of successfully collaborating with other...
Why Receptos Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 10, 2:49PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Receptos , a clinical-stage...
Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...
Receptos MS Drug Yields More Good Data; Stock Jumps
at Investor's Business Daily - Wed Sep 10, 10:58AM CDT
Biotech Receptos (RCPT) shot up more than 14% in morning trading on the stock market today, just shy of an all-time high, after it released more good data from a mid-stage clinical trial of its multiple-sclerosis drug. Receptos filed a late-breaking...
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 10, 10:17AM CDT
AbbVie's (ABBV) collaboration agreement with Infinity Pharmaceuticals (INFI) was one of the top stories in the biotech sector last week.
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
Business Wire - Wed Sep 10, 6:00AM CDT
--- Patients Most Uncomfortable Engaging in Candid Dialogue about More Private Symptoms -
J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig
at The Street - Mon Sep 08, 7:48AM CDT
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Why Baxter International Offers Great Reward for Minimal Risk
at The Street - Mon Sep 08, 5:00AM CDT
Wall Street is wrong to discount Baxter's value-creating potential.
Indexes Trim Losses But Remain Lower At Midday
at Investor's Business Daily - Fri Sep 05, 11:04AM CDT
The stock market came off morning lows at midday Friday, but remained lower as some notable leaders came under fire. The Nasdaq fell 0.3% while the S&P 500 and the Dow Jones industrial average were down 0.1%. Volume was running higher on the NYSE and...
Upcoming Conferences, Dividends, Regulatory Disclosures, and Acquisitions - Research Reports on Medtronic, Humana, Shire, Biogen and Covidien
PR Newswire - Fri Sep 05, 8:05AM CDT
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.70%
Comtex SmarTrend(R) - Thu Sep 04, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.78 to a high of $344.44. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $339.18 on volume of 827,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Diplomat to distribute Plegridy(TM) (peginterferon beta-1a) for treatment of multiple sclerosis
PR Newswire - Thu Sep 04, 3:42PM CDT
Diplomat, the nation's largest independent specialty pharmacy, announced that it will distribute Plegridy(TM) (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy(TM) was approved on August 15, 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be administered subcutaneously with the Plegridy Pen, a new, ready-to-use autoinjector, or a prefilled syringe.
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
Specialty Vaccine Company PaxVax Appoints Mark Meltz Executive Vice President and Chief Legal Officer
Business Wire - Wed Sep 03, 7:01AM CDT
PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice President and Chief Legal Officer. In this role, Mr. Meltz will oversee all legal, intellectual property, business development, government affairs, compliance and corporate governance matters for the company.
Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care
Business Wire - Wed Sep 03, 7:01AM CDT
--- Innovative Programs Reinforce Commitment to Improving the Lives of People Living with MS -
Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014
Business Wire - Tue Sep 02, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference 2014. The webcast will be live on Monday, September 8, 2014 at 2:00p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Watch For Today's Momo Momentum Stock: Biogen Idec (BIIB)
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple
Biogen: Moving From Collaboration To Innovation
at Investor's Business Daily - Fri Aug 29, 3:14PM CDT
In an industry as risky as biotechnology, it's easy to stick with a proven formula. But sometimes, managing for success means changing your strategic direction to avoid falling into a rut. After two decades of successfully collaborating with other...
